Authors | Agent | Study design | Target | Number | Response rate (DCR) | PFS (month) | OS (month) |
---|---|---|---|---|---|---|---|
Cytotoxic agents | |||||||
Loehrer et al. [29] | Pemetrexed | Ph II | - | 11 | NR | 1.3 | N/A |
Wakelee et al. [33] | Amrubicin | Ph II | - | 19 | 10.5Â % | 8.5 | 18.1 |
Liang et al. [46] | Pemetrexed | Retrosp | - | 10 | 10.0Â % | 6.5 | 12.7 |
Palmieri et al. [47] | Capecitabine + gemcitabine | Ph II | - | 8 | 37.5 % | 6 (3–10) | N/A |
The present study | S-1 | Retrosp | - | 14 | 42.9Â % | 8.1 | 30.0 |
Molecular targeted agents | |||||||
Thomas et al. [13] | Sunitinib | Ph II | c-KIT, PDGFR | 23 | 26Â % (65Â %) | 7.2 | Not reached |
Zucali et al. [14] | Everolimus | Ph II | mTOR | 12 | 25Â % (41Â %) | 12.1a | 24.0a |
Rajan et al. [48] | Cixutumumab | Ph II | IGF-1R | 12 | 0Â % | 1.7 | 8.4 |
Giaccone et al. [49] | Belinostat | Ph II | HDAC | 16 | 0Â % (50Â %) | 5.8 | 12.4 |
Besse et al. [50] | Milciclib (PHA-848125Â AC) | Ph II | CDK, src family | 26 | - | - | - |
Bedano et al. [51] | Erlotinib + bevacizumab | Ph II | EGFR, VEGF | 7 | 0 | N/A | N/A |
Kurup et al. [52] | Gefitinib | Ph II | EGFR | 7 | 0 | N/A | N/A |
Giaccone et al. [53] | Imatinib | Ph II | c-KIT mutation | 5 | 0 | N/A | N/A |
Loehrer et al. [54] | Octreotide + prednisone | Ph II | somatostatin receptor | 6 | 0 | 4.5 | 23.4 |
Gubens et al. [55] | Saracatinib (AZD0530) | Ph II | src family | 9 | 0 | 3.6 | 6.7 |